EXSCIENTIA
8.7.2021 10:02:52 CEST | Business Wire | Press release
Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the COVID-19 Therapeutics Accelerator. This is to expedite the optimisation of a new class of COVID-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform to design a novel class of inhibitors targeting the SARS-CoV-2’s main protease enzyme, Mpro , also known as 3CLpro , the causative agent of COVID-19. Mpro is essential for the replication of coronavirus, so administering an Mpro inhibitor to patients as a standalone antiviral or alongside other concurrent treatments could provide a useful frontline therapy.
Exscientia’s AI-based platform will be used to optimise the novel small molecule inhibitors into a therapeutic development candidate, designed to be active against SARS-CoV-2 and other coronaviruses. The project’s goal is to identify potential pan-coronavirus therapeutics that could be effective against COVID-19, and also new mutations or other SARS viruses that may emerge.
The new grant provided by the COVID-19 Therapeutics Accelerator - an initiative launched by the Gates Foundation, Wellcome, and Mastercard to speed up the response to the pandemic - comes in addition to recent backing from the Gates Foundation supporting Exscientia’s work in developing treatments for tuberculosis, malaria and non-hormonal contraceptives which began in January 2021. Under the new grant, Exscientia will receive $1.5 million which will be used to advance a development candidate on achieving defined milestones. The virus protease inhibitors will be designed using Exscientia’s AI-driven drug discovery platform, which delivers optimised compounds, fulfilling complex design goals faster and more effectively than with conventional drug discovery methods.
Dr. Denise Barrault, Senior Portfolio Manager at Exscientia, commented, “The danger of new emerging strains and mutations of coronavirus means there is an urgent need for new antiviral drugs in this pandemic alongside vaccines, to respond more quickly in potential future coronavirus pandemics. We believe that the world needs innovation to accelerate the discovery of more effective counter-measures for a range of infectious diseases, including COVID-19.”
Exscientia has built a track record of improving and accelerating drug discovery by advancing the first three completely AI-designed small molecule drug candidates into clinical trials. In addition to its own proprietary programmes, Exscientia has entered into collaborations with major pharmaceutical companies including Bristol Myers Squibb, Bayer, Sanofi and Dainippon Sumitomo, as well as multiple biotech companies. The company currently has more than 20 partners or wholly owned programmes for diseases involving cancer, immunology, the central nervous system, and genetic mutations.
ENDS
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005344/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services, Assai Software Partner to Advance Digital Twin-led Engineering Intelligence11.5.2026 12:30:00 CEST | Press release
Partnership in LTTS’ Sustainability segment strengthens AI-powered solutions for global energy leaders L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services signed a strategic agreement with Europe-based Assai Software Services, a leading Engineering Document Management Systems (EDMS) and Digital Twin solutions provider to develop advanced technology solutions and cater to the massive energy & utilities sector in Europe. The partnership in LTTS’ Sustainability segment will combine its engineering and delivery capabilities with Assai’s software expertise to address the growing complexity of asset-intensive projects for global energy leaders. By enabling seamless integration with Digital Twin technology, the alliance will deliver real-time asset visualization, traceability and governed engineering information across project lifecycles. LTTS has also established a dedicated Centre of Excellence (CoE) leveraging Assai’s platform to supp
Prodalim Announced its Q1’2026 Results Presenting Accelerated Growth in the Specialty Ingredients & Solutions Activity11.5.2026 12:03:00 CEST | Press release
SIS revenues (Specialty Ingredients & Solutions) grew 64% in Q1 into 19.7 million dollars (growth of 27% on a LFL1 basis).Group revenue for the quarter grew 4% into 91.5 million dollars.Adjusted EBITDA2 for the SIS activity grew 95% into 3.6 million dollars, reflecting an adjusted EBITDA margin of 18%.Adjusted net profit grew 19% into 3.9 million dollars.Cash flow from operating activities surged into 15.0 million dollars. Tsahi Barak, Chairman of the Board and CEO of the Company, stated: “We are pleased to report a strong quarter during which we continued to successfully implement the company’s business strategy, which emphasizes, among other things, significant and profitable growth in the Specialty Ingredients & Solutions activity and the expansion of Solos’ infrastructure, our dealcoholization division. We believe that the positive momentum in this activity will continue throughout the year, as we continuously work to leverage the many opportunities across the various markets. The
Corpay Partners With BVNK To Add Stablecoin Wallets for Global Customers11.5.2026 12:00:00 CEST | Press release
Corpay, Inc. (NYSE: CPAY), the leading corporate payments company, today announced that it is partnering with stablecoin infrastructure platform BVNK to provide stablecoin wallets and settlement capabilities to its global customer base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511711546/en/ The integration will enable Corpay’s customers to see a stablecoin balance alongside their fiat balances, and provide customers with embedded stablecoin wallets for sending, receiving, storing, and converting stablecoins within its platform. Customers will now have access to the always-on payment rails that operate beyond the limits of traditional banking hours and systems. Corpay will also integrate stablecoin rails in its treasury operations, reducing reliance on pre-funded accounts, improving capital efficiency, and improving the movement of funds across its global footprint outside of its own proprietary network. Corpay serve
Ant International Highlights Democratising AI and Strengthening Trust in 2025 Sustainability Report11.5.2026 11:17:00 CEST | Press release
Company now provides global account services to 1.6 mn SMEs, and credit access to over 30 mn underserved With the inclusion principle integrated into main innovation projects, Ant International now links 2 bn user accounts with 150 mn merchants through multi-layered partnerships, provides global account services to 1.6 mn SMEs, and helps over 30 mn underserved businesses and individuals access quality credit. As its global payment, global account and embedded finance services expand rapidly, it is accelerating investments in compliance capabilities and advanced security technologies to tackle evolving regulatory and risk environments. From basketball courts in New York to marine protection in Java Indonesia, we build extensive partnerships to protect the environment and empower local communities. Ant International, a leading global digital payment, digitisation and financial technology provider, today published its 2025 Sustainability Report, the 2nd since the Company began independent
Dryad Launches Gen-4-Pro Silvanet Wildfire Sensor, Setting New Standard in Ultra-Early Fire Detection11.5.2026 11:09:00 CEST | Press release
Next-generation technology delivers unmatched detection speed, accuracy, and connectivity for global wildfire prevention Dryad Networks, a global leader in ultra-early wildfire detection technology, today announced the launch and immediate availability of the Gen-4-Pro Silvanet Wildfire Sensor, the fourth generation of its industry-leading Silvanet solution. The new Gen-4-Pro sensor introduces significant advancements in detection capability, energy autonomy, and connectivity—further strengthening Dryad’s mission to protect forests, infrastructure, and communities from the growing threat of wildfires. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260510819235/en/ Silvanet Wildfire Sensor Gen4Pro enables ultra-early wildfire detection and environmental data monitoring. The Silvanet suite is a comprehensive wildfire detection system combining solar-powered gas sensors, a large-scale wireless IoT network, and cloud-based analy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom